Efficacy of Injectable Contraceptive and Oral Contraceptive Administered After Surgical Treatment of Endometriosis With Pain

Postoperative Intramuscular Depot Medroxyprogesterone Acetate Versus Continuous Oral Contraceptive for Pelvic Pain Associated With Endometriosis : Randomized Comparative Trial.

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01056042

Enrollment

112

Registered

2010-01-26

Start date

2007-06-30

Completion date

2011-10-31

Last updated

2014-10-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis

Keywords

pelvic pain, postoperative, medical therapy

Brief summary

Patients with endometriosis-associated pain have conservative surgery performed to remove all visible lesions. Then, patients are randomized into two groups. In the first group patients have depot medroxyprogesterone acetate injections every 3 months for a total of 6 months.In the second group patients have oral contraceptive combined pills everyday for 6 months. Patients are followed up on recurrence of pain for 1 year after medication.

Interventions

DRUGintramuscular depot medroxyprogesterone acetate

150 mg, Intramuscular, every 3 months

DRUGethinyl estradiol 30 micrograms, gestodene 75 micrograms

one tablet orally, everyday

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 45 Years

Healthy volunteers

Inclusion criteria

* Premenopausal women from 18 to 45 years of age with endometriosis-associated pain for at least 6 months who had conservative surgery performed.

Exclusion criteria

* Medical therapies for endometriosis other than NSAID within previous 6 months * Contraindication to the drugs * Wish to conceive * Request for extirpative surgery * Other pelvic pathology ( adenomyosis, chronic PID, submucous myoma uteri )

Design outcomes

Primary

Measure	Time frame
Patients' satisfaction with the treatment	1 year and 6 months

Secondary

Measure	Time frame
pain reduction and adverse side effects	1 year and 6 months

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026